YTN16-luc Orthotopic Mouse Model Service for Gastric Cancer

The YTN16-luc orthotopic mouse model of gastric cancer pairs an aggressive, immune-intact syngeneic tumor with real-time luciferase bioluminescence readouts, making it possible to visualize primary gastric tumor growth and lymphatic, hematogenous, and peritoneal spread from the earliest stages. Alfa Cytology builds and executes this model as a complete preclinical offering — covering stable luciferase line qualification, microsurgical orthotopic implantation into the gastric wall, scheduled in vivo imaging, treatment administration, and metastasis-focused endpoint analysis — so oncology programs can generate decision-ready efficacy data within a fully immunocompetent tumor microenvironment.

Overview of YTN16-luc Orthotopic Mouse Model for Gastric Cancer

The YTN16 cell line belongs to the first panel of transplantable murine gastric cancer lines reported in the literature, derived from an N-methyl-N-nitrosourea (MNU)-induced glandular stomach carcinoma that arose in a p53-heterozygous knockout mouse on a C57BL/6 background. Among its sibling subclones, YTN16 displays the most aggressive behavior: it engrafts with a 100% subcutaneous take rate and gives rise to spontaneous lung metastases, lymph node metastases, and peritoneal dissemination at notably high frequencies. Because YTN16 is a genuinely murine line, it grows robustly in immunocompetent C57BL/6 recipients — an attribute of particular value for immuno-oncology, where human xenografts in immunodeficient hosts cannot capture checkpoint blockade, T-cell infiltration, or cytokine-mediated tumor regulation.

Fig 1. Derivation and in vivo selection of the YTN16 murine gastric cancer cell line from MNU-induced gastric adenocarcinoma, resulting in a highly tumorigenic and metastatic syngeneic model. (Yamamoto, Masami, et al., 2018)

YTN16-luc is the firefly luciferase-expressing version of this line, generated by stable reporter transduction so that tumor cells emit a measurable photon signal upon D-luciferin administration. Implanted orthotopically into the gastric subserosa, the labeled cells develop focal primary tumors whose photon flux rises in proportion to viable tumor mass, while occult seeding to regional lymph nodes, lungs, and the peritoneal cavity becomes detectable well before gross lesions appear. This combination of aggressive metastatic biology and quantitative imaging has made the YTN16-luc orthotopic model a valuable system for profiling targeted agents (including FGFR4-directed strategies), benchmarking checkpoint inhibitors and combination regimens, and mapping the tempo and pattern of gastric cancer dissemination under treatment.

Cell Line Information: YTN16-luc

YTN16 is a murine gastric carcinoma subclone established through primary culture of an MNU-induced stomach tumor from a p53-heterozygous knockout C57BL/6 mouse, followed by in vivo selection and single-cell cloning. The YTN16-luc variant carries a stably integrated firefly luciferase reporter, enabling sensitive bioluminescence detection of tumor burden in vivo. Below is a summary of the key characteristics of this cell line.

Our Services

What sets Alfa Cytology apart in this space is the depth of practical, in-house expertise behind every YTN16-luc study: our scientists routinely handle aggressive syngeneic gastric lines, perform high-precision gastric wall implantation, and operate standardized imaging calendars that keep bioluminescence data comparable from cohort to cohort. From pilot feasibility runs through full efficacy studies with metastasis staging, Alfa Cytology manages the entire preclinical workflow under one roof, communicating proactively so your team always knows where each cohort stands and what the data mean for the next decision.

Workflow of YTN16-luc Orthotopic Mouse Model Construction

Developing a YTN16-luc orthotopic gastric cancer study demands close coordination between cell biology, microsurgery, and imaging. The sequence below reflects the standard operating flow, with each phase governed by written procedures to protect consistency, animal welfare, and data integrity.

1. Luciferase line qualification: YTN16-luc cultures are verified for strong, uniform reporter expression by luminescence assay, confirmed free of mycoplasma, and banked at low passage to preserve aggressive growth behavior.
2. Expansion and inoculum preparation: Qualified cells are expanded in vitro under controlled conditions, harvested at the appropriate confluency, and adjusted to the working concentration (for example, 1×10⁶ cells in a small-volume suspension suited to subserosal delivery).
3. Recipient animal preparation: Immunocompetent C57BL/6 mice are acclimatized, stratified by body weight, and moved into a sterile surgical environment with anesthesia and perioperative analgesia in place.
4. Orthotopic implantation: Through a limited midline laparotomy, the stomach is exteriorized and the YTN16-luc suspension is deposited slowly into the subserosal layer of the gastric body or antrum using a fine needle; the needle track is checked for reflux before layered wound closure.
5. Recovery and baseline imaging: Animals recover under observation with thermal support, and once stable receive D-luciferin for baseline whole-body bioluminescence imaging that documents engraftment and initial tumor signal.
6. Scheduled imaging and cohort balancing: Photon flux is measured on a fixed schedule together with body weight and clinical condition; animals are distributed into treatment arms on the basis of matched baseline signals to avoid cohort skew.
7. Necropsy and metastasis workup: At the defined endpoint, primary gastric tumors are excised and weighed, the abdominal cavity is systematically inspected, lymph nodes and lungs are collected, and ex vivo imaging plus histopathology confirm and stage metastatic involvement.

Fig 2. YTN16-luc orthotopic mouse model construction workflow.

Case Study-YTN16-luc Orthotopic Mouse Model Development

Alfa Cytology has employed the YTN16-luc orthotopic gastric cancer platform in a number of preclinical programs for biotechnology and pharmaceutical clients, where it served as the in vivo backbone for testing candidate compounds, antibody-based therapeutics, and combination regimens against orthotopically established gastric tumors. Across these programs, scheduled bioluminescence imaging provided sensitive, quantitative tracking of primary tumor expansion and early metastatic seeding, while terminal workups captured tumor weights, metastatic distribution, and histological confirmation of lesion identity. Where required, tumor tissue recovered from these studies was additionally banked for downstream molecular or immunological analysis. Because each program differs in scope and readouts, Alfa Cytology treats case details as project-specific — representative data and study outlines can be provided upon request.

Why Choose Alfa Cytology?

When your research question demands an immunocompetent gastric cancer model with genuine metastatic behavior, execution quality matters as much as the cell line itself. Alfa Cytology pairs the aggressive YTN16-luc platform with disciplined surgical technique, calibrated imaging practice, and responsive scientific communication, so that every dataset you receive is both rigorous and easy to interpret. Researchers choose us for reasons such as:

• Direct, hands-on proficiency with fast-growing syngeneic gastric lines and their handling demands.
• An immunocompetent C57BL/6 setting that captures checkpoint therapy, combination regimens, and immune microenvironment effects.
• Quantitative longitudinal bioluminescence that reveals metastatic spread earlier and with fewer animals.
• Surgical orthotopic technique refined to minimize leakage and standardize tumor initiation.
• A complete endpoint package covering primary tumor metrics, systematic metastasis staging, and histopathology.
• Single-point project ownership with regular updates and straightforward, decision-oriented reporting.

Contact Us

Ready to move your gastric cancer program into an immunocompetent orthotopic setting? Contact us to arrange a scientific discussion of your targets, dosing concepts, and endpoint needs. You can also reach out to Alfa Cytology for a tailored study proposal and quotation — our team is glad to design the right YTN16-luc experiment for your preclinical goals.

For research use only. Not intended for any clinical use.